Home › Trial NCT00100815
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
- Trial IDNCT00100815
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorRoswell Park Cancer Institute
- Enrollment50
- Start date2004-08
- ConditionsPancreatic Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.